Furthermore, attempts to apply trial sequential analysis (TSA) to these issues have also contributed to the debat . e
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, 5 4 With regard to secondary prevention of cardiovascular disease, the meta-analysis by Kwak and colleagues 1 found no proof of effectiveness for PUFAs. Later, a TSA that was based on the same data provided a stronger negative conclusion in terms of proof of no effectiveness (futility). 4 Likewise, with regard to the role of PUFAs to prevent atrial fibrillation, a meta-analysis showing no effectiveness was published, 2 followed by a TSA indicating . futility In this framework, the metaanalysis by Costanzo and associates 3 recently published in the Journal has been focused on the preoperative supplementation of PUFAs to prevent postoperative atrial fibrillation in heart surgery. The results of this meta-analysis were borderline, because most effectiveness indices were at the limits of statistical significance.
In an attempt to clarify the uncertainty surrounding the effectiveness of PUFAs for this indication, we undertook a TSA aimed at reexamining the same 8 trials evaluated by Costanzo and associates. 3 Our analysis considered the end point of postoperative atrial fibrillation. Main assumptions included 2-sided testing, risk of type 1 error of 5%, and power of 80%. The intervention effect was set at an anticipated 15% or 20% relative risk reduction, with the event rate in the control group assumed to be 30% (equal to the overall rate in the 8 control groups). As usual, the main result of TSA was expressed through the graph of cumulative z curve. With reference to this graph, the boundaries for concluding superiority or inferiority or futility were calculated according to the O'Brien-Fleming a-spending function. Our analysis was done with a specific statistical software package (TSA Viewer; Copenhagen Trial Unit, Copenhagen, Denmark).
Application of TSA to these 8 randomized trials generated an inconclusive result (Figure 1 ). In particular, our analysis estimated that the optimal information size would be 8614 or 4763 patients (according to the assumptions of relative risk reduction of 15% or 20%, respectively). At the cumulative number of 2687 patients (those included in the 8 trials published thus far), the z curve remained, in both graphs, quite far from intercepting 
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Application of trial sequential analysis to interpret the results of 8 placebo-controlled trials evaluating preoperati 3 -n ve polyunsaturat edfatty acids to prevent postoperative atrial fibrillation in heart surgery (A and B, expected 15% and -20% relative risk reductions, respectively). In both graphs, the z curve (blue) is composed of consecutive segments that correspond to individual trials; trials are plotted in chronologic order from left to right. The x-axis indicates the cumulative number of patients; the starting point of the z curve is by definition at x ¼ 0, (inclusion of no trials). At the cumulative number of 2687 included patients (8 trials), the curve is still in an inconclusive area, because none of the boundaries of superiority or inferiority or futility have been reached. The information-size analysis estimates that at least 8614 or 4763 patients (A and B, respectively) would be needed to reach a conclusion in terms of superiority or inferiority or futility. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61   62  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100  101  102  103  104  105  106  107  108  109  110  111  112  113  114  115  116  117  118  119  120  121  122 the boundary of superiority but at the same time did not reach the futility area.
In the light of the current evidence,
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the conclusion that PUFAs are effective for this clinical indication is not justified; on the other hand, neither can the conclusion of a proven ineffectiveness of PUFAs be made. Unless further positive trial results are made available, uncertainty remains regarding the effectiveness of PUFAs for this indication. Overall, if one considers that a clear proof of ineffectiveness has been obtained for two other important indications of PUF , As the overall picture of the therapeutic role of these agents seems to be extremely weak.
